Most investors have noticed that most stocks in the healthcare sector have declined to levels not seen in a while, making ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks to watch as Jim Cramer looked at market rationality. Cramer discussed ...

Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that’s expected to include a 40-year bond, a ...

Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

The move is part of the company’s plan to renegotiate drug prices across other developed nations ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

More than 80% of the potential $100 million in tax credits Eli Lilly could receive for its expansion in Kenosha County would ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.